BusinessAXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND SubmissionBy Nasdaq OMXDec 12, 2017, 2:01 PM UTC
BusinessCure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep DisordersBy Nasdaq OMXNov 7, 2017, 2:00 PM UTC
BusinessAXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency StudyBy Nasdaq OMXJun 19, 2017, 1:00 PM UTC
BusinessAXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.govBy Nasdaq OMXMay 15, 2017, 1:03 PM UTC
BusinessAXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.govBy Nasdaq OMXMay 15, 2017, 1:03 PM UTC
BusinessAXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.govBy Nasdaq OMXMay 15, 2017, 1:03 PM UTC
BusinessAXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.govBy Nasdaq OMXMay 15, 2017, 1:03 PM UTC
BusinessAXIM Biotech Enters Term Sheet Agreement With US API Company to Develop Bioequivalent Product to MarinolBy Nasdaq OMXMar 28, 2017, 1:01 PM UTC
